Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
01 juin 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
27 mai 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
01 mai 2020 06h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
30 avr. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
23 avr. 2020 07h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
13 avr. 2020 17h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., April 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
27 févr. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other...
Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
20 févr. 2020 07h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
13 févr. 2020 11h40 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...